TGTX

63.3402.37%
KH

Kenneth Hoberman

Independent Director

Mr. Kenneth Hoberman, also known as Ken, has been the Chief Operating Officer of Stemline Therapeutics, Inc. since 2012 and serves as its Corporate Secretary and was a key member of the founding team. He serves as Vice-Chairman at Lirum Therapeutics, Inc. since November 2021. Mr. Hoberman served as Vice President of Operations at Stemline Therapeutics, Inc. from March 2012 to March 2013. He served as the Head of Corporate Development at Stemline Therapeutics, Inc. He was a Consultant to Stemline since its founding in 2003. He served as Vice President of Corporate and Business Development of Keryx Biopharmaceuticals, Inc. He founded and served as Head of Business Development of Access Oncology, Inc. and was a key member of the transition team that led the acquisition of Access Oncology, Inc. by Keryx. He served as Managing Director at Hawkins BioVentures. He was instrumental in the TG Therapeutics, Inc's financings from early private, including institutional, rounds through the IPO and subsequent follow-on offerings. He has extensive financial, accounting, investor relations, corporate governance and business development experience including M&A, strategic alliances and partnerships both domestic and international. His operational expertise includes regulatory oversight, human resources, manufacturing and clinical development. He also led the team that originated, in-licensed and developed Auryxia™ which gained FDA approval in 2014. He has been a Director of TG Therapeutics, Inc. since December 17, 2014. He is a Director of Nuvectis Pharma, Inc. since July 2021. Mr. Hoberman received a B.S.B.A. degree in Finance from Boston University and completed post-baccalaureate studies at Columbia University.

Positions